DXCM: DexCom, Inc. - Summary | Jitta

DexCom, Inc.

NASDAQ:DXCM

Price
$57.56
Loss Chance
41.4%
7.23JITTA SCORE
17.16%Under Jitta Line
Jitta Ranking
10 / 718
95 / 4,228
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (65)
Recent Business Performance (83)
Financial Strength (82)
Return to Shareholders (60)
Competitive Advantage (88)
Jitta Signs
Revenue and EarningConsistent Growth in the past 5 years
Recent Business PerformanceEarning Growth Last Year
Operating MarginConsistent
Debt LevelLow Long Term Debt
Interest Coverage RatioVery Good
SG&A to SalesDecreasing
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
7.23
17.16%
3.07
403.38%
Health Care Equipment
5.57
1.71%
7.31
2.36%
7.35
38.29%
COMPANY DESCRIPTION
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.